Journal
EUROPEAN JOURNAL OF HAEMATOLOGY
Volume 93, Issue 3, Pages 179-186Publisher
WILEY
DOI: 10.1111/ejh.12356
Keywords
Sokal score; Hasford score; European Treatment and Outcome Study score; prognostic risk scores; chronic myeloid leukemia; tyrosine kinase inhibitors
Categories
Funding
- Novartis Pharmaceuticals
Ask authors/readers for more resources
The approval of multiple tyrosine kinase inhibitors targeting BCR-ABL has broadened the number of available therapeutic options for chronic myeloid leukemia in the chronic phase (CML-CP). This provides an impetus for optimizing prognostic risk score systems that can guide treatment decisions. Presently, three risk scores-the Sokal, Hasford, and European Treatment and Outcome Study (EUTOS) metrics-have been implemented clinically in CML-CP. While these three formulations all endeavor to gauge likely disease course, they differ from one another in several important respects, with potential implications for prognosis and therapy. Here, we review these risk scores and propose how prognostic systems in CML-CP might be refined to direct patients to optimally effective therapies as efficiently and accurately as possible.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available